An initiative for targeting inflammation as a disease-modifying strategy in Parkinson's disease (PD) will continue with the development of a novel medicine to protect nerve cells from damage, thanks to a recent grant from the Michael J. Fox Foundation for Parkinson's Research (MJFF).
Biotech (LBT) and the University of Nebraska Medical Center (UNMC) are
developing the drug, LBT-3627, as part of a strategy to pinpoint
inflammation symptoms as a way to fight PD. The grant
continues efforts that have shown earlier success.
According to Longevity Biotech, "LBT-3627
is a selective neuroprotective immunomodulatory agent targeting the
vasoactive intestinal peptide receptor 2 (VPAC2)."
The research team will look at ways of
protecting and repairing dopamine neurons impaired by the disease,
ascertaining optimal dosage and administration.
"Collectively these studies will
refine the therapeutic product profile for LBT-3627 as we head toward
initial clinical evaluation of this unique disease-modifying
strategy," Scott Shandler, co-founder and CEO of Longevity
Biotech, said. "We are excited about the future of LBT-3627 and
its potential to improve the lives of the millions of patients that
are affected each year by this devastating disease."
in Philadelphia, Longevity Biotech focuses on a category of potential
therapeutic drugs with the trade name Hybridtides -- synthetic peptides
based on work begun at the University of Wisconsin.
are pleased to support the LBT and UNMC teams as they work toward
addressing neuro-inflammation as a [new] strategy," Terina
Martinez, senior associate director of Research Programs at the
Michael J. Fox Foundation, said.
Actor's foundation backs novel drug for Parkinson's
Organizations in this Story
Want to get notified whenever we write about Longevity Biotech, Inc ?
Next time we write about Longevity Biotech, Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts